Syncona Regulatory News (SYNC)

Syncona Limited (the "Company")

Director Declaration

6 March 2024

In accordance with the requirements of the Listing Rule 9.6.14R, the Company advises the following change to directorships in other publicly quoted companies held by the following member of the Board:

Dr Julie Cherrington was appointed to Elevation Oncology, Inc. (Nasdaq: ELEV) on 4 March 2024.

Enquiries

Syncona Ltd

Alasdair Moodie

Tel: +44 (0) 20 3981 7940

Citco Fund Services (Guernsey) Limited

Company Secretary

Tel: +44 (0) 1481 758200

About Syncona:

Syncona's purpose is to invest to extend and enhance human life. We do this by creating and building companies to deliver transformational treatments to patients in areas of high unmet need.

Our strategy is to create, build and scale companies around exceptional science to create a diversified portfolio of 20-25 globally leading life science businesses, across development stage, modality and therapeutic areas, for the benefit of all our stakeholders. We focus on developing treatments for patients by working in close partnership with world-class academic founders and management teams. Our balance sheet underpins our strategy enabling us to take a long-term view as we look to improve the lives of patients with no or poor treatment options, build sustainable life science companies and deliver strong risk-adjusted returns to shareholders.